Scientific References – Publications
QPS Neuropharmacology
QPS encourages its scientists to publish and disseminate the results of their high quality research which is mostly done in close collaboration with our clients.
The following articles are hyperlinked to the original journal article or an abstract of the article:
Hepatic and neuronal phenotype of NPC1−/− mice
Estibaliz Santiago-Mujica, Stefanie Flunkert, Roland Rabl, Joerg Neddens, Tina Loeffler, Birgit Hutter-Paier.
Heliyon. 2019 Mar 14;5(3):e01293. doi: 10.1016/j.heliyon.2019.e01293
Correction: Further investigation of phenotypes and confounding factors of progressive ratio performance and feeding behavior in the BACHD rat model of Huntington disease.
Clemensson EKH, Clemensson LE, Fabry B, Flunkert S, Riess O, Wronski R, Nguyen HP.
PLoS One. 2019 Mar 7;14(3):e0213755. doi: 10.1371/journal.pone.0213755. eCollection 2019.
BACE1-cleavage of Sez6 and Sez6L is elevated in Niemann-Pick type C disease mouse brains.
Causevic M, Dominko K, Malnar M, Vidatic L, Cermak S, Pigoni M, Kuhn PH, Colombo A, Havas D, Flunkert S, McDonald J, Gunnersen JM, Hutter-Paier B, Tahirovic S, Windisch M, Krainc D, Lichtenthaler SF, Hecimovic S.
PLOS ONE. 2018 Jul 6;13(7):e0200344. doi: 10.1371/journal.pone.0200344.
Phosphorylation of different tau sites during progression of Alzheimer’s disease.
Neddens J, Temmel M, Flunkert S, Kerschbaumer B, Hoeller C, Loeffler T, Niederkofler V, Daum G, Attems J, Hutter-Paier B.
Acta Neuropathol Commun. 2018 Jun 29;6(1):52. doi: 10.1186/s40478-018-0557-6.
mTh1 driven expression of hTDP-43 results in typical ALS/FTLD neuropathological symptoms.
Scherz B, Rabl R, Flunkert S, Rohler S, Neddens J, Taub N, Temmel M, Panzenboeck U, Niederkofler V, Zimmermann R, Hutter-Paier B.
PLOS ONE. 2018 May 22;13(5):e0197674. doi: 10.1371/journal.pone.0197674.
Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer’s Disease.
Kutzsche J, Schemmert S, Tusche M, Neddens J, Rabl R, Jürgens D, Brener O, Willuweit A, Hutter-Paier B, Willbold D.
Molecules. 2017 Oct 10;22(10). pii: E1693. doi: 10.3390/molecules22101693
SEN1500, a novel oral amyloid-β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer’s disease.
Brunner D, Flunkert S, Neddens J, Duller S, Scopes DIC, Treherne JM, Hutter-Paier B.
Neurosci Lett. 2017 Sep 13. pii: S0304-3940(17)30770-X. doi: 10.1016/j.neulet.2017.09.028. [Epub ahead of print].
Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.
Collier TJ, Srivastava KR, Justman C, Grammatopoulous T, Hutter-Paier B, Prokesch M, Havas D, Rochet JC, Liu F, Jock K, de Oliveira P, Stirtz GL, Dettmer U, Sortwell CE, Feany MB, Lansbury P, Lapidus L, Paumier KL.
Neurobiol Dis. 2017 Jul 12. pii: S0969-9961(17)30159-6. doi: 10.1016/j.nbd.2017.07.007. [Epub ahead of print].
Glutaminyl Cyclase Inhibitor PQ912 improves cognition in mouse models of Alzheimer’s disease – studies on relation to effective target occupancy.
Hoffmann T, Meyer A, Heiser U, Kurat S, Bohme L, Kleinschmidt M, Buhring KU, Hutter-Paier B, Farcher M, Demuth HU, Lues I, Schilling S.
J Pharmacol Exp Ther. 2017 Apr 26. pii: jpet.117.240614. doi: 10.1124/jpet.117.240614.
Early and progressive microstructural brain changes in mice overexpressing human α-Synuclein detected by diffusion kurtosis imaging.
Khairnar A, Ruda-Kucerova J, Szabó N, Drazanova E, Arab A, Hutter-Paier B, Neddens J, Latta P, Starcuk Z Jr, Rektorova I.
Brain Behav Immun. 2017 Mar;61:197-208. doi: 10.1016/j.bbi.2016.11.027.
